CTSO
What one share of Cytosorbents holds
Surgical and Medical Instruments and Apparatus
We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Cytosorbents’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.62 |
|---|---|
| Profit | −$0.30 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.15 |
| Cash and investments | $0.07 |
| Debt | $0.27 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.37 | −$0.46 | $0.01 | −$0.27 | — | $0.05 |
| 2017 | $0.55 | −$0.32 | $0.04 | −$0.27 | — | $0.35 |
| 2018 | $0.73 | −$0.56 | $0.02 | −$0.37 | — | $0.53 |
| 2019 | $0.77 | −$0.60 | $0.02 | −$0.54 | — | $0.10 |
| 2020 | $1.06 | −$0.20 | $0.02 | −$0.16 | — | $1.83 |
| 2021 | $1.00 | −$0.57 | $0.08 | −$0.41 | — | $1.43 |
| 2022 | $0.80 | −$0.75 | $0.14 | −$0.79 | — | $0.81 |
| 2023 | $0.70 | −$0.65 | $0.01 | −$0.50 | — | $0.43 |
| 2024 | $0.65 | −$0.38 | $0.01 | −$0.27 | — | $0.20 |
| 2025 | $0.60 | −$0.13 | $0.00 | −$0.20 | — | $0.09 |